文献速递传染病防控与疫情报告免疫规划

用于全部九种血清型的非洲马瘟禁用感染性单动物(DISA)-DIVA疫苗平台的开发

Development of African horse sickness disabled infectious single animal (DISA)-DIVA vaccine platform applied for all nine serotypes.
PubMed 文献 · Vaccine · 2025-09-23

非洲马瘟是马属动物由媒介传播的病毒病,未免疫家马死亡率可达95%,现有减毒活疫苗不安全且无法区分感染与免疫。本研究基于基因组第10片段缺失开发了DISA-DIVA疫苗平台,通过交换第2和第6片段应用于全部九种血清型,获得DISA1至DISA9候选疫苗,并经多种体外方法验证,配套DIVA PCR检测已开发并验证。

要点

  • DISA-DIVA平台基于基因组第10片段缺失,完全消除毒力。
  • 通过交换第2和第6片段,平台覆盖全部九种AHSV血清型。
  • DISA1至DISA9经体外验证无毒力、不可由蠓传播、可与野型区分。

核心结论

  • DISA1至DISA9无毒力、不可由蠓传播、可与野型AHSV区分,现已准备在马属目标宿主中进行免疫攻毒实验以研究效力。

研究设计与样本

  • 基于反向遗传学构建AHS DISA-DIVA疫苗平台,利用基因组第10片段的可缺失缺失完全消除毒力,通过交换编码血清型特异性免疫显性外壳蛋白的第2和第6片段应用于全部九种AHSV血清型。
  • 获得九种候选疫苗DISA1至DISA9,并经多种体外方法广泛检查。
  • 开发并验证了针对基因组第10片段缺失区域的配套DIVA PCR检测。

主要发现

  • 基于先前对强毒AHSV的研究,DISA1至DISA9无毒力、不可由蠓传播、可与野型AHSV区分。
  • 九种DISA-DIVA候选疫苗现已准备在马属目标宿主中进行免疫攻毒实验以研究效力。

局限性

  • 原文指出DISA1至DISA9现已准备在马属目标宿主中进行免疫攻毒实验以研究效力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

African Horse Sickness (AHS) is a devastating vector-borne viral disease of equids with a mortality up to 95 % in naïve domestic horses. The causative African horse sickness virus (AHSV) is a distinct species of the genus Orbivirus of the family Sedoreoviridae, consisting of nine serotypes showing limited cross protection. AHSV is transmitted by Culicoides biting midges. Outbreaks cause huge economic losses in developing African countries. AHS has become a serious threat for countries outside Africa, since endemic Culicoides species in moderate climates appear competent vectors of the closely related prototype orbivirus, bluetongue virus. In the developed world, AHS outbreaks will result in losses in the equestrian industry and will have an enormous emotional impact on owners of leisure horses. Live-attenuated vaccine viruses (LAVs) are unsafe and differential detection of infected equids in LAV-vaccinated populations is not possible. Reverse genetics has paved the way to develop improved AHS vaccines, particularly with regard to vaccine safety and the DIVA principle (DIVA = Differentiating Infected from Vaccinated). Here, we developed an AHS Disabled Infectious Single Animal (DISA)-DIVA vaccine platform based on a dispensable deletion in genome segment 10 completely abolishing its virulence. The vaccine platform was applied for all nine AHSV serotypes by exchange of genome segments 2 and 6 encoding serotype specific immunodominant outer shell proteins. These nine promising AHS DISA-DIVA vaccines, named shortly DISA1 to DISA9 after their serotype, were extensively checked by several in vitro methods. The accompanying DIVA PCR-test targeting the deleted region in genome segment 10 was developed and validated. Based on previous research on virulent AHSV, DISA1 to DISA9 are not virulent, are not transmittable by midges, can be distinguished from wildtype AHSV, and are now ready for vaccination-challenge experiments in the equine target host to study efficacy.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. van Rijn PA, Wernery U, Feddema AJ, et al. Development of African horse sickness disabled infectious single animal (DISA)-DIVA vaccine platform applied for all nine serotypes. Vaccine. 2025. PMID: 40992078. doi:10.1016/j.vaccine.2025.127772

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。